Use of Adalimumab, a TNF-Alpha Inhibitor, is Associated with Paradoxical Psoriasis: Two Clinical Case Reports

The use of tumor necrosis factor (anti-TNF) antagonists has become a practice applied in the treatment various inflammatory diseases, such as psoriasis. However, Anti-TNF can, paradoxically, trigger side effects form psoriasiform or worsening pre-existing symptoms, patients with without previously diagnosed In view this, two case reports were described. First, we described 21-year-old female patient who used adalimumab for four months due to extensive suppurative hidradenitis. second case, related 32-year-old male severe Crohn's disease, Adalimumab three developed